Conditional deletion of Tsc1 in the female reproductive tract impedes normal oviductal and uterine function by enhancing mTORC1 signaling in mice

Molecular Human Reproduction

Volumn 19, Issue 7, 2013, Pages 463-472

  Daikoku, Takiko ^a   Yoshie, Mikihiro ^a   Xie, Huirong ^a   Sun, Xiaofei ^a   Cha, Jeeyeon ^a   Ellenson, Lora Hedrick ^b   Dey, Sudhansu K ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Mouse; Ovary; Oviduct; Tsc1; Uterus

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MUELLERIAN INHIBITING FACTOR; PROGESTERONE RECEPTOR; PROTEIN; TUBEROUS SCLEROSIS COMPLEX 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLASTOCYST; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO DEVELOPMENT; EMBRYO TRANSFER; EPITHELIUM HYPERPLASIA; FEMALE; FEMALE GENITAL SYSTEM; FERTILIZATION; FERTILIZATION IN VITRO; GENE DELETION; GENETIC RECOMBINATION; HYPERPLASIA; IN SITU HYBRIDIZATION; LEIOMYOSARCOMA; LONG TERM SURVIVAL; LOXP SITE; MOUSE; NONHUMAN; OVIDUCT; PHENOTYPE; PREGNANCY DISORDER; PREGNANCY OUTCOME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UTERUS; UTERUS GROWTH; VAGINA BLEEDING;

MOUSE; OVARY; OVIDUCT; TSC1; UTERUS;

ANIMALS; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; IMMUNOHISTOCHEMISTRY; MICE; MICE, MUTANT STRAINS; MULTIPROTEIN COMPLEXES; OVARY; OVIDUCTS; PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; UTERUS;

EID: 84880157619     PISSN: 13609947     EISSN: 14602407     Source Type: Journal    
DOI: 10.1093/molehr/gat016     Document Type: Article

References (31)

1. Adhikari D, Flohr G, Gorre N, Shen Y, Yang H, Lundin E, Lan Z, Gambello MJ, Liu K. Disruption of Tsc2 in oocytes leads to overactivation of the entire pool of primordial follicles. Mol Hum Reprod 2009;15:765-770.
2. Adhikari D, Zheng W, Shen Y, Gorre N, Hamalainen T, Cooney AJ, Huhtaniemi I, Lan ZJ, Liu K. Tsc/mTORC1 signaling in oocytes governs the quiescence and activation of primordial follicles. Hum Mol Genet 2010;19:397-410.
3. Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ. Molecular genetic advances in tuberous sclerosis. Hum Genet 2000;107:97-114.
4. Contreras CM, Akbay EA, Gallardo TD, Haynie JM, Sharma S, Tagao O, Bardeesy N, Takahashi M, Settleman J, Wong KK et al. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibito monotherapy. Dis Model Mech 2010;3:181-193.
5. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;355:1345-1356.
6. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372:657-668.
7. Daikoku T, Tranguch S, Trofimova IN, Dinulescu DM, Jacks T, Nikitin AY, Connolly DC, Dey SK. Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res 2006;66:2527-2531.
8. Daikoku T, Hirota Y, Tranguch S, Joshi AR, DeMayo FJ, Lydon JP, Ellenson LH, Dey SK. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res 2008; 68:5619-5627.
9. Daikoku T, Jackson L, Besnard V, Whitsett J, Ellenson LH, Dey SK. Cell-specific conditional deletion of Pten in the uterus results in differential phenotypes. Gynecol Oncol 2011;122:424-429.
10. Darb-Esfahani S, Faggad A, Noske A, Weichert W, Buckendahl AC, Muller B, Budczies J, Roske A, Dietel M, Denkert C. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol 2009;135:933-941.
11. Di Cristofano A, Ellenson LH. Endometrial carcinoma. Annu Rev Pathol 2007;2:57-85.
12. Fan HY, Liu Z, Cahill N, Richards JS. Targeted disruption of Pten in ovarian granulosa cells enhances ovulation and extends the life span of luteal cells. J Mol Endocrinol 2008;22:2128-2140.
13. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer cell 2007;12:9-22.
14. Hirota Y, Cha J, YoshieM, DaikokuT, Dey SK. Heightened uterinemammalian target of rapamycin complex 1 (mTORC1) signaling provokes pretermbirth in mice. Proc Natl Acad Sci U S A 2011;108:18073-8.
15. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013;493:338-345.
16. Katajisto P, Vallenius T, Vaahtomeri K, Ekman N, Udd L, Tiainen M, Makela TP. The LKB1 tumor suppressor kinase in human disease. Biochim Biophys Acta 2007;1775:63-75.
17. Kobayashi T, Minowa O, Sugitani Y, Takai S, Mitani H, Kobayashi E, Noda T, Hino O. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc Natl Acad Sci USA 2001;98:8762-8767.
18. Tsc1 in oviduct-uterine signaling 471 Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 2005;14(Spec No. 2):R251-R258.
19. Lu KH, Wu W, Dave B, Slomovitz BM, Burke TW, Munsell MF, Broaddus RR, Walker CL. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res 2008;14:2543-2550.
20. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-262.
21. Mak BC, Yeung RS. The tuberous sclerosis complex genes in tumor development. Cancer Invest 2004;22:588-603.
22. McCampbell AS, Broaddus RR, Walker CL. Loss of inhibitory insulin receptor substrate-1 phosphorylation: an early event in endometrial hyperplasia and progression to carcinoma. Cell Cycle 2010; 9:2698-2699.
23. Memarzadeh S, Zong Y, Janzen DM, Goldstein AS, Cheng D, Kurita T, Schafenacker AM, Huang J, Witte ON. Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. Proc Natl Acad Sci USA 2010;107:17298-17303.
24. Paria BC, Huet-Hudson YM, Dey SK. Blastocyst's state of activity determines the 'window' of implantation in the receptive mouse uterus. Proc Natl Acad Sci USA 1993;90:10159-10162.
25. Reddy P, Liu L, Adhikari D, Jagarlamudi K, Rajareddy S, Shen Y, Du C, Tang W, Hamalainen T, Peng SL et al. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science 2008;319:611-613.
26. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmstrom P, Memeo L et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007;104:7564-7569.
27. Sun X, Wang H, Okabe M, Mackie K, Kingsley PJ, Marnett LJ, Cravatt BF, Dey SK. Genetic loss of Faah compromises male fertility in mice. Biol Reprod 2009;80:235-242.
28. Tanaka Y, Park JH, Tanwar PS, Kaneko-Tarui T, Mittal S, Lee HJ, Teixeira JM. Deletion of tuberous sclerosis 1 in somatic cells of the murine reproductive tract causes female infertility. Endocrinology 2012; 153:404-416.
29. Tanwar PS, Kaneko-Tarui T, Zhang L, Tanaka Y, Crum CP, Teixeira JM. Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian target of rapamycin Complex 1. PLoS Genet 2012;8:e1002906.
30. Torres ML, Weaver AL, Kumar S, Uccella S, Famuyide AO, Cliby WA, Dowdy SC, Gostout BS, Mariani A. Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol 2012;120:998-1004.
31. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35